JP2004518709A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004518709A5 JP2004518709A5 JP2002563916A JP2002563916A JP2004518709A5 JP 2004518709 A5 JP2004518709 A5 JP 2004518709A5 JP 2002563916 A JP2002563916 A JP 2002563916A JP 2002563916 A JP2002563916 A JP 2002563916A JP 2004518709 A5 JP2004518709 A5 JP 2004518709A5
- Authority
- JP
- Japan
- Prior art keywords
- matrix former
- formulation according
- formulation
- hydrophobic matrix
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 26
- 238000009472 formulation Methods 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims 15
- 230000002209 hydrophobic effect Effects 0.000 claims 9
- 239000007962 solid dispersion Substances 0.000 claims 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000000194 fatty acid Substances 0.000 claims 5
- 229930195729 fatty acid Natural products 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- -1 fatty acid esters Chemical class 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000155 melt Substances 0.000 claims 3
- 230000008018 melting Effects 0.000 claims 3
- 238000002844 melting Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 230000008014 freezing Effects 0.000 claims 2
- 238000007710 freezing Methods 0.000 claims 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229960000502 poloxamer Drugs 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 235000021360 Myristic acid Nutrition 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000008118 PEG 6000 Substances 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 1
- 229960000997 bicalutamide Drugs 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000004203 carnauba wax Substances 0.000 claims 1
- 235000013869 carnauba wax Nutrition 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 229940082500 cetostearyl alcohol Drugs 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000001804 emulsifying effect Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 229960003580 felodipine Drugs 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 229920001992 poloxamer 407 Polymers 0.000 claims 1
- 229940044476 poloxamer 407 Drugs 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229940012831 stearyl alcohol Drugs 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0100478A SE0100478D0 (sv) | 2001-02-13 | 2001-02-13 | Novel formulation |
| SE0100477A SE0100477D0 (sv) | 2001-02-13 | 2001-02-13 | Novel formulation |
| PCT/SE2002/000228 WO2002064121A1 (en) | 2001-02-13 | 2002-02-08 | Novel modified released formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004518709A JP2004518709A (ja) | 2004-06-24 |
| JP2004518709A5 true JP2004518709A5 (enExample) | 2008-10-02 |
Family
ID=26655389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002563914A Pending JP2004518708A (ja) | 2001-02-13 | 2002-02-08 | 放出性が改良された新規な処方物 |
| JP2002563916A Pending JP2004518709A (ja) | 2001-02-13 | 2002-02-08 | 新規放出修飾製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002563914A Pending JP2004518708A (ja) | 2001-02-13 | 2002-02-08 | 放出性が改良された新規な処方物 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20040067252A1 (enExample) |
| EP (2) | EP1361868A1 (enExample) |
| JP (2) | JP2004518708A (enExample) |
| KR (1) | KR20040058103A (enExample) |
| CN (2) | CN1491105A (enExample) |
| AT (1) | ATE324871T1 (enExample) |
| AU (1) | AU2002228579B2 (enExample) |
| BR (1) | BR0206825A (enExample) |
| CA (2) | CA2434542A1 (enExample) |
| DE (1) | DE60211130T2 (enExample) |
| DK (1) | DK1368006T3 (enExample) |
| ES (1) | ES2261643T3 (enExample) |
| IL (1) | IL157075A0 (enExample) |
| MX (1) | MXPA03007092A (enExample) |
| NO (1) | NO20033564L (enExample) |
| NZ (2) | NZ526993A (enExample) |
| PT (1) | PT1368006E (enExample) |
| WO (2) | WO2002064118A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| BR0314787A (pt) * | 2002-09-28 | 2005-07-26 | Mcneil Ppc Inc | Forma de dosagem de liberação modificada |
| SE0301904D0 (sv) | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | Novel imidazopyridine compound II with therapeutic effect |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| JP2007507425A (ja) * | 2003-08-29 | 2007-03-29 | ダイノゲン ファーマシューティカルズ，インコーポレイテッド | 胃腸管運動障害を処置するために有用な組成物 |
| WO2005053656A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride |
| WO2005053652A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
| WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
| AU2004294813A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride |
| SE0303451D0 (sv) * | 2003-12-18 | 2003-12-18 | Astrazeneca Ab | New compounds |
| MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| HRP20141001T1 (hr) | 2006-03-16 | 2014-12-05 | Euro-Celtique S.A. | Farmaceutski sferoidi |
| JP2011516412A (ja) | 2008-03-05 | 2011-05-26 | ビカス セラピューティクス，エルエルシー | 癌および粘膜炎の治療のための組成物および方法 |
| WO2011000126A1 (zh) * | 2009-06-29 | 2011-01-06 | Liu Yu | 脂溶性药物组合物、制备方法及其用途 |
| EP2921486B1 (en) | 2009-08-07 | 2017-09-27 | American Life Science Pharmaceuticals, Inc. | Compositions and methods for treating beta-amyloid related diseases |
| US20130165880A1 (en) | 2010-09-17 | 2013-06-27 | David T. Amos | Antimicrobial disposable absorbent articles |
| WO2012070030A1 (en) * | 2010-11-26 | 2012-05-31 | University Of The Witwatersrand, Johannesburg | A pharmaceutical composition |
| CA2859174C (en) | 2011-12-12 | 2019-03-05 | Orbis Biosciences, Inc. | Sustained release particle formulations |
| US20130149383A1 (en) * | 2011-12-12 | 2013-06-13 | Cory Berkland | Sustained release particle formulations of guaifenesin |
| EP3319595A4 (en) * | 2015-06-30 | 2019-04-03 | Kemin Industries, Inc. | ENCAPSULATED ACTIVE SUBSTANCES FOR CONTROLLED ENTERAL ACTIVE COMPOSITION |
| US9889120B2 (en) | 2016-01-14 | 2018-02-13 | Vicus Therapeutics, Llc | Combination drug therapies for cancer and methods of making and using them |
| DE102017108054A1 (de) | 2017-04-13 | 2018-10-18 | Natura Werk Gebr. Hiller GmbH & Co. KG | Essbare Zusammensetzung zur Verdauungsförderung |
| WO2021142395A1 (en) | 2020-01-10 | 2021-07-15 | Consynance Therapeutics, Inc. | Therapeutic combinations of drugs and methods of using them |
| US20250101427A1 (en) | 2021-07-22 | 2025-03-27 | The Regents Of The University Of California | Compositions and methods for using purified human rna editing enzymes |
| WO2023184282A1 (en) * | 2022-03-30 | 2023-10-05 | Guizhou Sinorda Biomedicine Co., Ltd | X842 formulation |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL248553A (enExample) * | 1959-02-18 | |||
| NL194389C (nl) * | 1984-06-14 | 2002-03-04 | Novartis Ag | Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager. |
| US4629621A (en) * | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
| US5015479A (en) * | 1987-02-02 | 1991-05-14 | Seamus Mulligan | Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine |
| US4956182A (en) * | 1989-03-16 | 1990-09-11 | Bristol-Myers Company | Direct compression cholestyramine tablet and solvent-free coating therefor |
| US5405617A (en) * | 1991-11-07 | 1995-04-11 | Mcneil-Ppc, Inc. | Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals |
| US5281420A (en) * | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
| US5433951A (en) * | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
| KR100354702B1 (ko) * | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
| NZ270439A (en) * | 1995-02-02 | 1996-04-26 | Bernard Charles Sherman | Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer |
| US5851555A (en) * | 1997-08-15 | 1998-12-22 | Fuisz Technologies Ltd. | Controlled release dosage forms containing water soluble drugs |
| SE9801526D0 (sv) * | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
| US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
-
2002
- 2002-02-08 PT PT02710645T patent/PT1368006E/pt unknown
- 2002-02-08 EP EP02711597A patent/EP1361868A1/en not_active Withdrawn
- 2002-02-08 US US10/467,723 patent/US20040067252A1/en not_active Abandoned
- 2002-02-08 CN CNA028049063A patent/CN1491105A/zh active Pending
- 2002-02-08 US US10/467,900 patent/US20040067256A1/en not_active Abandoned
- 2002-02-08 NZ NZ526993A patent/NZ526993A/en unknown
- 2002-02-08 ES ES02710645T patent/ES2261643T3/es not_active Expired - Lifetime
- 2002-02-08 DE DE60211130T patent/DE60211130T2/de not_active Expired - Fee Related
- 2002-02-08 EP EP02710645A patent/EP1368006B1/en not_active Expired - Lifetime
- 2002-02-08 JP JP2002563914A patent/JP2004518708A/ja active Pending
- 2002-02-08 NZ NZ526994A patent/NZ526994A/en unknown
- 2002-02-08 MX MXPA03007092A patent/MXPA03007092A/es active IP Right Grant
- 2002-02-08 BR BR0206825-7A patent/BR0206825A/pt not_active IP Right Cessation
- 2002-02-08 KR KR10-2003-7010577A patent/KR20040058103A/ko not_active Abandoned
- 2002-02-08 DK DK02710645T patent/DK1368006T3/da active
- 2002-02-08 WO PCT/SE2002/000227 patent/WO2002064118A1/en not_active Ceased
- 2002-02-08 CN CNA028049144A patent/CN1491104A/zh active Pending
- 2002-02-08 JP JP2002563916A patent/JP2004518709A/ja active Pending
- 2002-02-08 CA CA002434542A patent/CA2434542A1/en not_active Abandoned
- 2002-02-08 IL IL15707502A patent/IL157075A0/xx unknown
- 2002-02-08 AT AT02710645T patent/ATE324871T1/de not_active IP Right Cessation
- 2002-02-08 WO PCT/SE2002/000228 patent/WO2002064121A1/en not_active Ceased
- 2002-02-08 AU AU2002228579A patent/AU2002228579B2/en not_active Ceased
- 2002-02-08 CA CA002434835A patent/CA2434835A1/en not_active Abandoned
-
2003
- 2003-08-12 NO NO20033564A patent/NO20033564L/no not_active Application Discontinuation
-
2007
- 2007-05-14 US US11/748,366 patent/US20080118560A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004518709A5 (enExample) | ||
| DE60129573T2 (de) | Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat | |
| EP1587497B1 (de) | Verfahren zur herstellung einer oralen arzneiform mit unmittelbarem zerfall und wirkstofffreisetzung | |
| JP2893191B2 (ja) | 放出制御性マトリックス剤 | |
| EP1368006B1 (en) | Novel modified released formulation | |
| US9616025B2 (en) | Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment | |
| EP1972336A1 (en) | Hot-melt micropellets | |
| AU2002228579A1 (en) | Novel modified released formulation | |
| US20220257772A1 (en) | Preparation of lipophilic active ingredients | |
| JP2004525887A (ja) | 新規フェノフィブラート錠剤 | |
| KR102363727B1 (ko) | 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 | |
| KR20070119700A (ko) | 페노피브레이트 및 계면 활성제 혼합물을 함유하는 제제 | |
| CN101618020A (zh) | 二氢吡啶类钙离子拮抗剂的固体自乳化口服给药系统及其制备方法 | |
| MX2007011858A (es) | Formulaciones mejoradas de fenofibrato que contienen mentol o peg/poloxamero. | |
| JPH0530810B2 (enExample) | ||
| CN101401788B (zh) | 联苯双酯自乳化制剂及其制备方法 | |
| WO2012035409A1 (en) | Sustained release compositions of anti-alzheimer's agents | |
| JP2010260803A (ja) | キサンタンガム被覆水溶性糖類及び圧縮成形製剤 | |
| JPH0460090B2 (enExample) | ||
| JP2760012B2 (ja) | 持続性細粒剤 | |
| JP2006514672A (ja) | 疎水性物質を徐放剤として含有する制御性放出製剤 | |
| JP2729494B2 (ja) | 安定な細粒剤 | |
| KR20020038591A (ko) | 경구용 의약 조성물 | |
| JP2013047282A (ja) | フェノフィブラート含有組成物 | |
| HK1059740B (en) | Novel modified released formulation |